Your browser doesn't support javascript.
loading
Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity.
Kciuk, Mateusz; Gielecinska, Adrianna; Mujwar, Somdutt; Kolat, Damian; Kaluzinska-Kolat, Zaneta; Celik, Ismail; Kontek, Renata.
Afiliação
  • Kciuk M; Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland.
  • Gielecinska A; Doctoral School of Exact and Natural Sciences, University of Lodz, 90-237 Lodz, Poland.
  • Mujwar S; Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland.
  • Kolat D; Doctoral School of Exact and Natural Sciences, University of Lodz, 90-237 Lodz, Poland.
  • Kaluzinska-Kolat Z; Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India.
  • Celik I; Department of Experimental Surgery, Faculty of Medicine, Medical University of Lodz, 90-136 Lodz, Poland.
  • Kontek R; Department of Experimental Surgery, Faculty of Medicine, Medical University of Lodz, 90-136 Lodz, Poland.
Cells ; 12(4)2023 02 19.
Article em En | MEDLINE | ID: mdl-36831326
Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX's action are not fully understood. Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen species (ROS) production, apoptosis, senescence, autophagy, ferroptosis, and pyroptosis induction, as well as its immunomodulatory role. This review aims to collect information on the anticancer mechanisms of DOX as well as its influence on anti-tumor immune response, providing a rationale behind the importance of DOX in modern cancer therapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doxorrubicina / Neoplasias Limite: Humans Idioma: En Revista: Cells Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doxorrubicina / Neoplasias Limite: Humans Idioma: En Revista: Cells Ano de publicação: 2023 Tipo de documento: Article